Journal of the Neurological Sciences
Volume 287, Issue 1 , Pages 64-68 , 15 December 2009

Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson's disease patients

  • Rey-Yue Yuan

      Affiliations

    • Department of Neurology, Taipei Medical University Hospital, Taipei, Taiwan
    • ,
  • Jau-Jiuan Sheu

      Affiliations

    • Department of Neurology, Taipei Medical University Hospital, Taipei, Taiwan
    • ,
  • Jia-Ming Yu

      Affiliations

    • Department of Neurology, Taipei Medical University Hospital, Taipei, Taiwan
    • ,
  • Chaur-Jong Hu

      Affiliations

    • Department of Neurology, Taipei Medical University Hospital, Taipei, Taiwan
    • ,
  • Ing-Jy Tseng

      Affiliations

    • College of Nursing, Taipei Medical University, Taipei, Taiwan
    • ,
  • Chun-Sum Ho

      Affiliations

    • Department of Neurology, Taipei Medical University Hospital, Taipei, Taiwan
    • ,
  • Ching-Ying Yeh

      Affiliations

    • Department of Public Health, School of Medicine, Taipei Medical University, Taipei, Taiwan
    • ,
  • Ya-Lin Hung

      Affiliations

    • Department of Neurology, Taipei Medical University Hospital, Taipei, Taiwan
    • ,
  • Tsuey-Ru Chiang

      Affiliations

    • Department of Neurology, Cathay General Hospital, No. 280 Ren-Ai Road, Taipei, Taiwan
    • Corresponding Author InformationCorresponding author. Tel.: +886 2 27372181x8608; fax: +886 2 27378561.

Received 5 May 2009 ,Revised 3 September 2009 ,Accepted 8 September 2009.

References 

  1. Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet. 1999;354:407–413
  2. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 2002;346:2007–2008
  3. Allain P, Le Bouil A, Cordillet E, Le Quay L, Bagheri H, Montastruc JL. Sulfate and cysteine levels in the plasma of patients with Parkinson's disease. Neurotoxicology. 1995;16:527–529
  4. Kuhn W, Roebroek R, Blom H, van Oppenraaij D, Muller T. Hyperhomocysteinaemia in Parkinson's disease. J Neurol. 1998;245:811–812
  5. Kuhn W, Roebroek R, Blom H, van Oppenraaij D, Przuntek H, Kretschmer A, et al. Elevated plasma levels of homocysteine in Parkinson's disease. Eur Neurol. 1998;40:225–227
  6. Muller T, Werne B, Fowler B, Kuhn W. Nigral endothelial dysfunction, homocysteine, and Parkinson's disease. Lancet. 1999;354:126–127
  7. Muller T, Kuhn W. Neurotoxicity of levodopa: treatment-associated homocysteine increase. Nat Clin Pract Neuro. 2007;3:E1
  8. Blandini F, Fancellu R, Martignoni E, Mangiagalli A, Pacchetti C, Samuele A, et al. Plasma homocysteine and L-DOPA metabolism in patients with Parkinson disease. Clin Chem. 2001;47:1102–1104
  9. Muller T, Woitalla D, Hauptmann B, Fowler B, Kuhn W. Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease. Neurosci Lett. 2001;308:54–56
  10. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111–113
  11. Weisberg IS, Jacques PF, Selhub J, Bostom AG, Chen Z, Curtis Ellison R, et al. The 1298A−>C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine. Atherosclerosis. 2001;156:409–415
  12. Castro R, Rivera I, Ravasco P, Jakobs C, Blom HJ, Camilo ME, et al. 5, 10-Methylenetetrahydrofolate reductase 677C−>T and 1298A−>C mutations are genetic determinants of elevated homocysteine. QJM. 2003;96:297–303
  13. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab. 1998;64:169–172
  14. Yasui K, Kowa H, Nakaso K, Takeshima T, Nakashima K. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology. 2000;55:437–440
  15. Kuhn W, Hummel T, Woitalla D, Muller T. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology. 2001;56:281;author reply-2
  16. Brattstrom L. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology. 2001;56:281;author reply-2
  17. Woitalla D, Kuhn W, Muller T. MTHFR C677T polymorphism, folic acid and hyperhomocysteinemia in levodopa treated patients with Parkinson's disease. J Neural Transm Suppl. 2004;15–20
  18. Religa D, Czyzewski K, Styczynska M, Peplonska B, Lokk J, Chodakowska-Zebrowska M, et al. Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease. Neurosci Lett. 2006;404:56–60
  19. Todorovic Z, Dzoljic E, Novakovic I, Mirkovic D, Stojanovic R, Nesic Z, et al. Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy. J Neurol Sci. 2006;248:56–61
  20. Camicioli RM, Bouchard TP, Somerville MJ. Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients. Mov Disord. 2009;24:176–182
  21. Caccamo D, Gorgone G, Curro M, Parisi G, Di Iorio W, Menichetti C, et al. Effect of MTHFR polymorphisms on hyperhomocysteinemia in levodopa-treated Parkinsonian patients. Neuromolecular Med. 2007;9:249–254
  22. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181–184
  23. Kara I, Sazci A, Ergul E, Kaya G, Kilic G. Association of the C677T and A1298C polymorphisms in the 5, 10 methylenetetrahydrofolate reductase gene in patients with migraine risk. Brain Res Mol Brain Res. 2003;111:84–90
  24. Miller JW, Selhub J, Nadeau MR, Thomas CA, Feldman RG, Wolf PA. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology. 2003;60:1125–1129
  25. Zoccolella S, Lamberti P, Armenise E, de Mari M, Lamberti SV, Mastronardi R, et al. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications. Parkinsonism Relat Disord. 2005;11:131–133
  26. Yasui K, Nakaso K, Kowa H, Takeshima T, Nakashima K. Levodopa-induced hyperhomocysteinaemia in Parkinson's disease. Acta Neurol Scand. 2003;108:66–67
  27. O'Suilleabhain PE, Bottiglieri T, Dewey RB, Sharma S, Diaz-Arrastia R. Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease. Mov Disord. 2004;19:1403–1408
  28. O'Suilleabhain P, Diaz-Arrastia R. Levodopa elevates homocysteine: is this a problem?. Arch Neurol. 2004;61:633–634
  29. Lamberti P, Zoccolella S, Armenise E, Lamberti SV, Fraddosio A, de Mari M, et al. Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration. Eur J Neurol. 2005;12:365–368
  30. Postuma RB, Espay AJ, Zadikoff C, Suchowersky O, Martin WR, Lafontaine AL, et al. Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study. Neurology. 2006;66:1941–1943
  31. Nakaso K, Yasui K, Kowa H, Kusumi M, Ueda K, Yoshimoto Y, et al. Hypertrophy of IMC of carotid artery in Parkinson's disease is associated with L-DOPA, homocysteine, and MTHFR genotype. J Neurol Sci. 2003;207:19–23
  32. Rogers JD, Sanchez-Saffon A, Frol AB, Diaz-Arrastia R. Elevated plasma homocysteine levels in patients treated with levodopa. Association with vascular disease. Arch Neurol. 2003;60:59–64
  33. O'Suilleabhain PE, Sung V, Hernandez C, Lacritz L, Dewey RJ, Bottiglieri T, et al. Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch Neurol. 2004;61:865–868
  34. Zoccolella S, Lamberti P, Iliceto G, Diroma C, Armenise E, Defazio G, et al. Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions. Clin Chem Lab Med. 2005;43:1107–1110
  35. Ozer F, Meral H, Hanoglu L, Aydemir T, Yilsen M, Cetin S, et al. Plasma homocysteine levels in patients treated with levodopa: motor and cognitive associations. Neurol Res. 2006;28:853–858
  36. Zoccolella S, Iliceto G, deMari M, Livrea P, Lamberti P. Management of L-Dopa related hyperhomocysteinemia: catechol-O-methyltransferase (COMT) inhibitors or B vitamins? Results from a review. Clin Chem Lab Med. 2007;45:1607–1613

PII: S0022-510X(09)00849-1

doi: 10.1016/j.jns.2009.09.007

Journal of the Neurological Sciences
Volume 287, Issue 1 , Pages 64-68 , 15 December 2009

Article Tools